A novel risk classification paradigm for patients with impaired glucose tolerance and high cardiovascular risk

American Journal of Cardiology

Volumn 112, Issue 2, 2013, Pages 231-237

  Bethel, M Angelyn ^a,b   Chacra, Antonio R ^c   Deedwania, Prakash ^d   Fulcher, Gregory R ^e   Holman, Rury R ^a   Jenssen, Trond ^f   Kahn, Steven E ^g,h   Levitt, Naomi S ⁱ   McMurray, John J V ^j   Califf, Robert M ^k   Raptis, Sotirios A ^l   Thomas, Laine ^b   Sun, Jie Lena ^b   Haffner, Steven M ^m  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF SYDNEY   (Australia)

^f OSLO UNIVERSITY HOSPITAL   (Norway)

^g VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^h UNIVERSITY OF WASHINGTON   (United States)

ⁱ UNIVERSITY OF CAPE TOWN   (South Africa)

^j UNIVERSITY OF GLASGOW   (United Kingdom)

^k DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^m NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C;

ADULT; ARTICLE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DISEASE COURSE; DYSGLYCEMIA; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

CARDIOVASCULAR DISEASES; DIABETES MELLITUS; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; TIME FACTORS;

EID: 84879838811     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2013.03.019     Document Type: Article

References (21)

1. M. Bartnik, L. Rydén, R. Ferrari, K. Malmberg, K. Pyörälä, M. Simoons, E. Standl, J. Soler-Soler, and J. Ohrvik The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart Eur Heart J 25 2004 1880 1890
2. A. Norhammar, A. Tenerz, G. Nilsson, A. Hamsten, S. Efendíc, L. Rydén, and K. Malmberg Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study Lancet 359 2002 2140 2144
3. D.Y. Hu, C.Y. Pan, J.M. Yu China Heart Survey Group The relationship between coronary artery disease and abnormal glucose regulation in China: the China Heart Survey Eur Heart J 27 2006 2573 2579
4. D. Mozaffarian, R. Marfisi, G. Levantesi, M.G. Silletta, L. Tavazzi, G. Tognoni, F. Valagussa, and R. Marchioli Incidence of new-onset diabetes and impaired fasting glucose in patients with recent myocardial infarction and the effect of clinical and lifestyle risk factors Lancet 370 2007 667 675
5. P. Pajunen, H. Koukkunen, M. Ketonen, T. Jerkkola, P. Immonen-Räihä, P. Kärjä-Koskenkari, M. Mähönen, M. Niemelä, K. Kuulasmaa, P. Palomäki, J. Mustonen, A. Lehtonen, M. Arstila, T. Vuorenmaa, S. Lehto, H. Miettinen, A. Juolevi, J. Torppa, J. Tuomilehto, Y.A. Kesäniemi, K. Pyörälä, and V. Salomaa Five-year risk of developing clinical diabetes after first myocardial infarction; the FINAMI study Diabet Med 22 2005 1334 1337
6. L. Rydén, E. Standl, M. Bartnik, G. Van den Berghe, J. Betteridge, M.J. de Boer, F. Cosentino, B. Jönsson, M. Laakso, K. Malmberg, S. Priori, J. Ostergren, J. Tuomilehto, I. Thrainsdottir, I. Vanhorebeek, M. Stramba-Badiale, P. Lindgren, Q. Qiao, S.G. Priori, J.J. Blanc, A. Budaj, J. Camm, V. Dean, J. Deckers, K. Dickstein, J. Lekakis, K. McGregor, M. Metra, J. Morais, A. Osterspey, J. Tamargo, J.L. Zamorano, J.W. Deckers, M. Bertrand, B. Charbonnel, E. Erdmann, E. Ferrannini, A. Flyvbjerg, H. Gohlke, J.R. Juanatey, I. Graham, P.F. Monteiro, K. Parhofer, K. Pyörälä, I. Raz, G. Schernthaner, M. Volpe, and D. Wood Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary Eur Heart J 28 2007 88 136
7. J. Drozda Jr., J.V. Messer, J. Spertus, B. Abramowitz, K. Alexander, C.T. Beam, R.O. Bonow, J.S. Burkiewicz, M. Crouch, D.C. Goff Jr., R. Hellman, T. James 3rd, M.L. King, E.A. Machado Jr., E. Ortiz, M. O'Toole, S.D. Persell, J.M. Pines, F.J. Rybicki, L.B. Sadwin, J.D. Sikkema, P.K. Smith, P.J. Torcson, and J.B. Wong ACCF/AHA/AMA-PCPI 2011 performance measures for adults with coronary artery disease and hypertension: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures and the American Medical Association-Physician Consortium for Performance Improvement J Am Coll Cardiol 58 2011 316 336
8. R.M. Califf, M. Boolell, S.M. Haffner, M.A. Bethel, J. McMurray, A. Duggal, R.R. Holman NAVIGATOR Study Group Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial Am Heart J 156 2008 623 632
9. R.R. Holman, S.M. Haffner, J.J. McMurray, M.A. Bethel, B. Holzhauer, T.A. Hua, Y. Belenkov, M. Boolell, J.B. Buse, B.M. Buckley, A.R. Chacra, F.T. Chiang, B. Charbonnel, C.C. Chow, M.J. Davies, P. Deedwania, P. Diem, D. Einhorn, V. Fonseca, G.R. Fulcher, Z. Gaciong, S. Gaztambide, T. Giles, E. Horton, H. Ilkova, T. Jenssen, S.E. Kahn, H. Krum, M. Laakso, L.A. Leiter, N.S. Levitt, V. Mareev, F. Martinez, C. Masson, T. Mazzone, E. Meaney, R. Nesto, C. Pan, R. Prager, S.A. Raptis, G.E. Rutten, H. Sandstroem, F. Schaper, A. Scheen, O. Schmitz, I. Sinay, V. Soska, S. Stender, G. Tamás, G. Tognoni, J. Tuomilehto, A.S. Villamil, J. Vozár, and R.M. Califf Effect of nateglinide on the incidence of diabetes and cardiovascular events N Engl J Med 362 2010 1463 1476
10. P. Allison Survival Analysis Using SAS: A Practical Guide 2nd ed. 2010 SAS Institute Cary, NC
11. F.E. Harrell Jr., K.L. Lee, and D.B. Mark Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors Stat Med 15 1996 361 387
12. F.E. Harrell Jr. Regression Modeling Strategies 2001 Springer New York, NY
13. J.L. Chiasson, R.G. Josse, R. Gomis, M. Hanefeld, A. Karasik, and M. Laakso Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial Lancet 359 2002 2072 2077
14. W.C. Knowler, E. Barrett-Connor, S.E. Fowler, R.F. Hamman, J.M. Lachin, E.A. Walker, D.M. Nathan Diabetes Prevention Program Research Group Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin N Engl J Med 346 2002 393 403
15. DREAM Trial Investigators Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial Lancet 368 2006 1096 1105
16. J. Lindstrom, and J. Tuomilehto The diabetes risk score: a practical tool to predict type 2 diabetes risk Diabetes Care 26 2003 725 731
17. M.P. Stern, K. Williams, and S.M. Haffner Identification of persons at high risk for type 2 diabets mellitus: do we need the oral glucose tolerance test? Ann Intern Med 136 2002 575 581
18. C.A. Dasanu, S. Lamana, and G. Trikudanathan Thrombocytopenia, NAFLD, and metabolic syndrome: is there a link? South Med J 103 2010 1071
19. L.A. Adams Biomarkers of liver fibrosis J Gastroenterol Hepatol 26 2011 802 809
20. P. Calès, J. Boursier, S. Bertrais, F. Oberti, Y. Gallois, I. Fouchard-Hubert, N. Dib, J.P. Zarski, M.C. Rousselet multicentric groups (SNIFF 14 & 17, ANRS HC EP 23 Fibrostar) Diagnosis of different liver fibrosis characteristics by blood tests in non-alcoholic fatty liver disease Liver Int 30 2010 1346 1354
21. American Diabetes Association Standards of medical care in diabetes - 2011 Diabetes Care 34 suppl 1 2011 S11 S61